DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial
- PMID: 24829493
- PMCID: PMC4144116
- DOI: 10.3945/ajcn.113.081133
DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial
Abstract
Background: It is well recognized that amounts of trans and saturated fats should be minimized in Western diets; however, considerable debate remains regarding optimal amounts of dietary n-9, n-6, and n-3 fatty acids.
Objective: The objective was to examine the effects of varying n-9, n-6, and longer-chain n-3 fatty acid composition on markers of coronary heart disease (CHD) risk.
Design: A randomized, double-blind, 5-period, crossover design was used. Each 4-wk treatment period was separated by 4-wk washout intervals. Volunteers with abdominal obesity consumed each of 5 identical weight-maintaining, fixed-composition diets with one of the following treatment oils (60 g/3000 kcal) in beverages: 1) conventional canola oil (Canola; n-9 rich), 2) high-oleic acid canola oil with docosahexaenoic acid (CanolaDHA; n-9 and n-3 rich), 3) a blend of corn and safflower oil (25:75) (CornSaff; n-6 rich), 4) a blend of flax and safflower oils (60:40) (FlaxSaff; n-6 and short-chain n-3 rich), or 5) high-oleic acid canola oil (CanolaOleic; highest in n-9).
Results: One hundred thirty individuals completed the trial. At endpoint, total cholesterol (TC) was lowest after the FlaxSaff phase (P < 0.05 compared with Canola and CanolaDHA) and highest after the CanolaDHA phase (P < 0.05 compared with CornSaff, FlaxSaff, and CanolaOleic). Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were highest, and triglycerides were lowest, after CanolaDHA (P < 0.05 compared with the other diets). All diets decreased TC and LDL cholesterol from baseline to treatment endpoint (P < 0.05). CanolaDHA was the only diet that increased HDL cholesterol from baseline (3.5 ± 1.8%; P < 0.05) and produced the greatest reduction in triglycerides (-20.7 ± 3.8%; P < 0.001) and in systolic blood pressure (-3.3 ± 0.8%; P < 0.001) compared with the other diets (P < 0.05). Percentage reductions in Framingham 10-y CHD risk scores (FRS) from baseline were greatest after CanolaDHA (-19.0 ± 3.1%; P < 0.001) than after other treatments (P < 0.05).
Conclusion: Consumption of CanolaDHA, a novel DHA-rich canola oil, improves HDL cholesterol, triglycerides, and blood pressure, thereby reducing FRS compared with other oils varying in unsaturated fatty acid composition. This trial was registered at www.clinicaltrials.gov as NCT01351012.
© 2014 American Society for Nutrition.
Figures



Similar articles
-
Plasma fatty acid changes following consumption of dietary oils containing n-3, n-6, and n-9 fatty acids at different proportions: preliminary findings of the Canola Oil Multicenter Intervention Trial (COMIT).Trials. 2014 Apr 23;15:136. doi: 10.1186/1745-6215-15-136. Trials. 2014. PMID: 24754911 Free PMC article. Clinical Trial.
-
Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.Vascul Pharmacol. 2016 Dec;87:60-65. doi: 10.1016/j.vph.2016.06.007. Epub 2016 Jun 30. Vascul Pharmacol. 2016. PMID: 27374222 Clinical Trial.
-
Effects of canola and high-oleic-acid canola oils on abdominal fat mass in individuals with central obesity.Obesity (Silver Spring). 2016 Nov;24(11):2261-2268. doi: 10.1002/oby.21584. Obesity (Silver Spring). 2016. PMID: 27804268 Free PMC article. Clinical Trial.
-
A systematic review of high-oleic vegetable oil substitutions for other fats and oils on cardiovascular disease risk factors: implications for novel high-oleic soybean oils.Adv Nutr. 2015 Nov 13;6(6):674-93. doi: 10.3945/an.115.008979. Print 2015 Nov. Adv Nutr. 2015. PMID: 26567193 Free PMC article.
-
Effects of Canola Oil Consumption on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.J Am Coll Nutr. 2019 Feb;38(2):185-196. doi: 10.1080/07315724.2018.1475270. Epub 2018 Oct 31. J Am Coll Nutr. 2019. PMID: 30381009
Cited by
-
The effect of canola oil compared with sesame and sesame-canola oil on cardio-metabolic biomarkers in patients with type 2 diabetes: Design and research protocol of a randomized, triple-blind, three-way, crossover clinical trial.ARYA Atheroscler. 2019 Jul;15(4):168-178. doi: 10.22122/arya.v15i4.1940. ARYA Atheroscler. 2019. PMID: 31819750 Free PMC article.
-
The effects of sesame, canola, and sesame-canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial.Eur J Nutr. 2022 Oct;61(7):3499-3516. doi: 10.1007/s00394-022-02898-9. Epub 2022 May 21. Eur J Nutr. 2022. PMID: 35596008 Clinical Trial.
-
High-oleic canola oil consumption enriches LDL particle cholesteryl oleate content and reduces LDL proteoglycan binding in humans.Atherosclerosis. 2015 Feb;238(2):231-8. doi: 10.1016/j.atherosclerosis.2014.12.010. Epub 2014 Dec 9. Atherosclerosis. 2015. PMID: 25528432 Free PMC article. Clinical Trial.
-
Saturated Fatty Acids Consumed in Smoothies Increase Glucose and Metabolic Load Index in Young Adults Compared to Polyunsaturated Omega-3-Fatty Acids.Nutrients. 2023 Jan 27;15(3):642. doi: 10.3390/nu15030642. Nutrients. 2023. PMID: 36771349 Free PMC article.
-
Diets Enriched with Conventional or High-Oleic Acid Canola Oils Lower Atherogenic Lipids and Lipoproteins Compared to a Diet with a Western Fatty Acid Profile in Adults with Central Adiposity.J Nutr. 2019 Mar 1;149(3):471-478. doi: 10.1093/jn/nxy307. J Nutr. 2019. PMID: 30773586 Free PMC article. Clinical Trial.
References
-
- Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014;160:398–406. - PubMed
-
- Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n−3 and n−6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83:1483S–93S. - PubMed
-
- Bergouignan A, Momken I, Schoeller DA, Simon C, Blanc S. Metabolic fate of saturated and monounsaturated dietary fats: the Mediterranean diet revisited from epidemiological evidence to cellular mechanisms. Prog Lipid Res 2009;48:128–47. - PubMed
-
- Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747–57. - PubMed
-
- O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart 2013;99:159–62. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical